ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Rating) was the target of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 3,840,000 shares, a growth of 5.2% from the February 13th total of 3,650,000 shares. Based on an average trading volume of 174,100 shares, the days-to-cover ratio is presently 22.1 days. Approximately 21.9% of the company’s shares are short sold.
ALX Oncology Stock Performance
ALX Oncology stock opened at $4.77 on Friday. The firm’s fifty day moving average price is $7.88 and its 200-day moving average price is $10.14. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.57 and a current ratio of 9.57. The stock has a market cap of $194.90 million, a P/E ratio of -1.57 and a beta of 1.76. ALX Oncology has a fifty-two week low of $4.66 and a fifty-two week high of $20.40.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on ALXO shares. Credit Suisse Group dropped their price objective on shares of ALX Oncology from $38.00 to $34.00 and set an “outperform” rating on the stock in a report on Friday, March 10th. UBS Group lowered their target price on shares of ALX Oncology from $31.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, HC Wainwright lowered their target price on shares of ALX Oncology from $65.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, March 10th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $29.83.
Hedge Funds Weigh In On ALX Oncology
ALX Oncology Company Profile
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors.
- Get a free copy of the StockNews.com research report on ALX Oncology (ALXO)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.